Now Playing
Opinion|Videos|June 25, 2024
Adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
Advertisement
Episodes in this series
- While the follow-up data for the
AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?- Efficacy of preventing RSV-related lower respiratory tract disease
- Adverse effects
- Trial limitations
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases
2
Achieving Optimal LDL-C Helps Prevent Neoatherosclerosis, Late Stent Failure in Patients With STEMI
3
FDA Approves First Oral GLP-1 for Weight Management
4
FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia
5